| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anabolic Agents | 55 | 2024 | 256 | 11.330 |
Why?
|
| Androgens | 30 | 2024 | 1286 | 6.540 |
Why?
|
| Body Image | 34 | 2020 | 638 | 4.090 |
Why?
|
| Substance-Related Disorders | 70 | 2023 | 4420 | 3.900 |
Why?
|
| Testosterone Congeners | 12 | 2023 | 62 | 3.680 |
Why?
|
| Weight Lifting | 26 | 2024 | 130 | 3.490 |
Why?
|
| Performance-Enhancing Substances | 6 | 2017 | 30 | 2.890 |
Why?
|
| Doping in Sports | 13 | 2018 | 62 | 2.530 |
Why?
|
| Bulimia | 35 | 2008 | 400 | 1.740 |
Why?
|
| Marijuana Abuse | 19 | 2008 | 411 | 1.620 |
Why?
|
| Hypogonadism | 7 | 2022 | 798 | 1.570 |
Why?
|
| Body Dysmorphic Disorders | 5 | 2022 | 243 | 1.540 |
Why?
|
| Steroids | 7 | 2024 | 929 | 1.500 |
Why?
|
| Hallucinogens | 9 | 2018 | 197 | 1.490 |
Why?
|
| Testosterone | 19 | 2024 | 2472 | 1.200 |
Why?
|
| Child Abuse, Sexual | 13 | 2005 | 403 | 1.130 |
Why?
|
| Somatoform Disorders | 14 | 2006 | 423 | 1.070 |
Why?
|
| Cognition Disorders | 12 | 2015 | 3980 | 0.990 |
Why?
|
| Mood Disorders | 20 | 2020 | 1127 | 0.880 |
Why?
|
| Men | 4 | 2006 | 65 | 0.870 |
Why?
|
| Antidepressive Agents | 26 | 2017 | 2897 | 0.860 |
Why?
|
| Self Medication | 4 | 2017 | 117 | 0.850 |
Why?
|
| Hyperphagia | 22 | 1986 | 139 | 0.810 |
Why?
|
| Psychoses, Substance-Induced | 6 | 2010 | 99 | 0.790 |
Why?
|
| Repression, Psychology | 6 | 2001 | 46 | 0.760 |
Why?
|
| Heterosexuality | 3 | 2017 | 309 | 0.740 |
Why?
|
| Depressive Disorder | 47 | 2005 | 3728 | 0.730 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2018 | 1988 | 0.710 |
Why?
|
| Public Health | 5 | 2018 | 2669 | 0.700 |
Why?
|
| Fibromyalgia | 12 | 2008 | 405 | 0.690 |
Why?
|
| Unsafe Sex | 2 | 2019 | 238 | 0.680 |
Why?
|
| Athletes | 4 | 2018 | 1137 | 0.640 |
Why?
|
| Neuroleptic Malignant Syndrome | 10 | 2007 | 74 | 0.630 |
Why?
|
| Binge-Eating Disorder | 2 | 2010 | 147 | 0.630 |
Why?
|
| Adult | 212 | 2024 | 221210 | 0.620 |
Why?
|
| Bipolar Disorder | 40 | 2013 | 5092 | 0.620 |
Why?
|
| Cross-Cultural Comparison | 8 | 2005 | 635 | 0.620 |
Why?
|
| Human Growth Hormone | 2 | 2013 | 642 | 0.570 |
Why?
|
| Neuropsychological Tests | 15 | 2024 | 7054 | 0.560 |
Why?
|
| Personality Disorders | 8 | 2010 | 722 | 0.560 |
Why?
|
| Psychiatric Status Rating Scales | 41 | 2014 | 6019 | 0.550 |
Why?
|
| Amnesia | 4 | 2006 | 257 | 0.540 |
Why?
|
| Psychiatry | 8 | 2018 | 1693 | 0.530 |
Why?
|
| Bulimia Nervosa | 3 | 2008 | 206 | 0.530 |
Why?
|
| Culture | 3 | 2012 | 623 | 0.530 |
Why?
|
| Humans | 316 | 2024 | 761596 | 0.520 |
Why?
|
| Obsessive-Compulsive Disorder | 6 | 2018 | 1491 | 0.520 |
Why?
|
| Male | 196 | 2024 | 360846 | 0.520 |
Why?
|
| Marijuana Smoking | 7 | 2006 | 258 | 0.510 |
Why?
|
| Cognition | 6 | 2024 | 6992 | 0.500 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 4 | 2011 | 65 | 0.500 |
Why?
|
| Lysergic Acid Diethylamide | 4 | 2006 | 47 | 0.490 |
Why?
|
| Memory | 10 | 2012 | 2193 | 0.490 |
Why?
|
| Mental Disorders | 30 | 2018 | 6845 | 0.460 |
Why?
|
| Polypharmacy | 1 | 2017 | 306 | 0.460 |
Why?
|
| Anorexia Nervosa | 19 | 2008 | 1361 | 0.450 |
Why?
|
| Body Constitution | 6 | 2002 | 273 | 0.450 |
Why?
|
| Dissociative Disorders | 4 | 2001 | 234 | 0.430 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2017 | 2118 | 0.420 |
Why?
|
| Gender Identity | 7 | 2006 | 766 | 0.410 |
Why?
|
| Attitude to Health | 4 | 2011 | 2025 | 0.400 |
Why?
|
| Tendon Injuries | 1 | 2015 | 328 | 0.390 |
Why?
|
| Valproic Acid | 11 | 2000 | 443 | 0.390 |
Why?
|
| Amphetamine-Related Disorders | 2 | 2010 | 80 | 0.380 |
Why?
|
| Aggression | 6 | 2003 | 750 | 0.380 |
Why?
|
| Sexual Behavior | 8 | 2017 | 2180 | 0.380 |
Why?
|
| Family Health | 4 | 2006 | 1257 | 0.370 |
Why?
|
| Brain | 13 | 2019 | 27121 | 0.370 |
Why?
|
| Serotonin Agents | 1 | 2011 | 29 | 0.370 |
Why?
|
| Cultural Characteristics | 2 | 2011 | 251 | 0.360 |
Why?
|
| Family | 13 | 2008 | 3195 | 0.360 |
Why?
|
| Cannabinoids | 4 | 2003 | 172 | 0.360 |
Why?
|
| Prevalence | 19 | 2019 | 15733 | 0.350 |
Why?
|
| Electroconvulsive Therapy | 4 | 2010 | 500 | 0.350 |
Why?
|
| Behavioral Symptoms | 1 | 2012 | 186 | 0.350 |
Why?
|
| Delusions | 7 | 1994 | 298 | 0.350 |
Why?
|
| Attitude of Health Personnel | 5 | 2018 | 3889 | 0.350 |
Why?
|
| Adolescent | 90 | 2018 | 88326 | 0.340 |
Why?
|
| Erythropoietin | 1 | 2013 | 719 | 0.320 |
Why?
|
| Middle Aged | 102 | 2024 | 220921 | 0.320 |
Why?
|
| Communicable Diseases | 1 | 2017 | 875 | 0.310 |
Why?
|
| Methamphetamine | 2 | 2010 | 165 | 0.310 |
Why?
|
| Life Change Events | 3 | 2006 | 952 | 0.310 |
Why?
|
| tau Proteins | 1 | 2019 | 2095 | 0.300 |
Why?
|
| San Francisco | 2 | 2019 | 162 | 0.300 |
Why?
|
| Self Concept | 7 | 2011 | 1045 | 0.290 |
Why?
|
| Internet | 3 | 2013 | 3093 | 0.290 |
Why?
|
| Attention | 6 | 2012 | 2396 | 0.280 |
Why?
|
| Personal Satisfaction | 5 | 2005 | 644 | 0.280 |
Why?
|
| Social Perception | 1 | 2011 | 433 | 0.280 |
Why?
|
| Female | 171 | 2023 | 392705 | 0.280 |
Why?
|
| Antipsychotic Agents | 15 | 2010 | 3067 | 0.270 |
Why?
|
| Haloperidol | 2 | 2007 | 389 | 0.270 |
Why?
|
| Lithium | 14 | 1993 | 596 | 0.270 |
Why?
|
| Central Nervous System Stimulants | 3 | 2010 | 1177 | 0.270 |
Why?
|
| Psychotherapy | 6 | 2001 | 1647 | 0.270 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2008 | 625 | 0.270 |
Why?
|
| Photic Stimulation | 1 | 2012 | 1987 | 0.270 |
Why?
|
| Space Perception | 2 | 2006 | 465 | 0.260 |
Why?
|
| Comorbidity | 27 | 2012 | 10508 | 0.260 |
Why?
|
| Mescaline | 1 | 2005 | 7 | 0.260 |
Why?
|
| Crime | 4 | 2021 | 203 | 0.260 |
Why?
|
| Cluster Headache | 1 | 2006 | 54 | 0.260 |
Why?
|
| Behavior | 1 | 2009 | 541 | 0.260 |
Why?
|
| Fingers | 1 | 2009 | 507 | 0.260 |
Why?
|
| Coronary Vessels | 1 | 2017 | 3096 | 0.260 |
Why?
|
| Mental Recall | 5 | 2004 | 1221 | 0.250 |
Why?
|
| Violence | 4 | 2021 | 937 | 0.250 |
Why?
|
| Muscle, Skeletal | 7 | 2017 | 4948 | 0.250 |
Why?
|
| Amyloid beta-Peptides | 1 | 2019 | 3839 | 0.250 |
Why?
|
| Cross-Sectional Studies | 16 | 2023 | 26129 | 0.250 |
Why?
|
| Depressive Disorder, Major | 6 | 2017 | 4762 | 0.250 |
Why?
|
| Students | 11 | 2001 | 1741 | 0.250 |
Why?
|
| Infertility, Male | 1 | 2008 | 395 | 0.240 |
Why?
|
| Perceptual Distortion | 1 | 2004 | 36 | 0.240 |
Why?
|
| Women | 1 | 2006 | 223 | 0.240 |
Why?
|
| Terminology as Topic | 9 | 2003 | 1530 | 0.240 |
Why?
|
| Psychophysiologic Disorders | 3 | 2001 | 221 | 0.240 |
Why?
|
| Affect | 6 | 2000 | 1486 | 0.240 |
Why?
|
| Glutamic Acid | 3 | 2017 | 1176 | 0.240 |
Why?
|
| Akathisia, Drug-Induced | 3 | 1997 | 67 | 0.230 |
Why?
|
| Quality of Life | 5 | 2024 | 13367 | 0.230 |
Why?
|
| Salivary Glands | 1 | 2006 | 229 | 0.230 |
Why?
|
| Dementia | 1 | 2019 | 2689 | 0.230 |
Why?
|
| Ventricular Function, Left | 1 | 2017 | 3879 | 0.230 |
Why?
|
| Mass Media | 2 | 2002 | 303 | 0.230 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2017 | 3769 | 0.230 |
Why?
|
| Substance Abuse Detection | 4 | 2011 | 301 | 0.230 |
Why?
|
| Fluoxetine | 8 | 1996 | 733 | 0.220 |
Why?
|
| Malpractice | 2 | 2001 | 556 | 0.220 |
Why?
|
| Glutamine | 2 | 2017 | 577 | 0.220 |
Why?
|
| Stress Disorders, Post-Traumatic | 7 | 2006 | 4575 | 0.220 |
Why?
|
| Fathers | 1 | 2006 | 376 | 0.210 |
Why?
|
| Testis | 3 | 2022 | 794 | 0.210 |
Why?
|
| Fatigue Syndrome, Chronic | 4 | 2008 | 215 | 0.210 |
Why?
|
| Appetite Depressants | 1 | 2003 | 108 | 0.200 |
Why?
|
| Trazodone | 7 | 1989 | 68 | 0.200 |
Why?
|
| Gyrus Cinguli | 4 | 2017 | 1115 | 0.200 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2003 | 166 | 0.200 |
Why?
|
| Indians, North American | 1 | 2005 | 352 | 0.190 |
Why?
|
| Case-Control Studies | 17 | 2017 | 22176 | 0.190 |
Why?
|
| Systole | 2 | 2017 | 936 | 0.190 |
Why?
|
| Sports | 7 | 2018 | 705 | 0.190 |
Why?
|
| Awareness | 2 | 1996 | 648 | 0.190 |
Why?
|
| Diastole | 2 | 2017 | 782 | 0.190 |
Why?
|
| Dietary Supplements | 3 | 2012 | 3415 | 0.190 |
Why?
|
| Societies, Medical | 1 | 2013 | 3905 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2020 | 10766 | 0.190 |
Why?
|
| Attitude | 2 | 2006 | 775 | 0.190 |
Why?
|
| Drug Information Services | 1 | 2001 | 51 | 0.180 |
Why?
|
| Perceptual Disorders | 1 | 2003 | 198 | 0.180 |
Why?
|
| Compulsive Behavior | 2 | 1999 | 117 | 0.180 |
Why?
|
| Pattern Recognition, Visual | 1 | 2006 | 823 | 0.180 |
Why?
|
| Life Style | 6 | 2001 | 3917 | 0.180 |
Why?
|
| Risk-Taking | 4 | 2017 | 1038 | 0.180 |
Why?
|
| Somatotypes | 4 | 2005 | 41 | 0.180 |
Why?
|
| Homosexuality, Male | 4 | 2004 | 1334 | 0.170 |
Why?
|
| Branchial Region | 2 | 2009 | 37 | 0.170 |
Why?
|
| Sex | 1 | 1999 | 53 | 0.170 |
Why?
|
| Double-Blind Method | 21 | 2011 | 12341 | 0.160 |
Why?
|
| Athletic Performance | 2 | 2018 | 111 | 0.160 |
Why?
|
| Ephedrine | 2 | 2001 | 52 | 0.160 |
Why?
|
| Insulin | 1 | 2013 | 6597 | 0.160 |
Why?
|
| Interviews as Topic | 3 | 2015 | 2696 | 0.160 |
Why?
|
| Child Behavior | 1 | 2005 | 847 | 0.160 |
Why?
|
| Austria | 9 | 2003 | 207 | 0.160 |
Why?
|
| Play and Playthings | 1 | 1999 | 85 | 0.160 |
Why?
|
| Phenotype | 2 | 2007 | 16592 | 0.160 |
Why?
|
| Models, Statistical | 1 | 2013 | 5079 | 0.160 |
Why?
|
| Young Adult | 14 | 2019 | 59260 | 0.160 |
Why?
|
| Social Behavior | 2 | 2005 | 1135 | 0.150 |
Why?
|
| Rape | 1 | 1999 | 131 | 0.150 |
Why?
|
| Publishing | 1 | 2006 | 833 | 0.150 |
Why?
|
| Research | 3 | 2005 | 1982 | 0.150 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2019 | 141 | 0.150 |
Why?
|
| Sex Characteristics | 1 | 2009 | 2639 | 0.150 |
Why?
|
| Desensitization, Psychologic | 1 | 1998 | 27 | 0.150 |
Why?
|
| Visual Perception | 3 | 2004 | 1389 | 0.150 |
Why?
|
| Factitious Disorders | 6 | 1988 | 39 | 0.150 |
Why?
|
| Diagnosis, Differential | 19 | 2009 | 12973 | 0.150 |
Why?
|
| Psychotic Disorders | 14 | 1997 | 3223 | 0.150 |
Why?
|
| Sex Factors | 13 | 2006 | 10554 | 0.150 |
Why?
|
| Anticonvulsants | 3 | 2009 | 1906 | 0.150 |
Why?
|
| Borderline Personality Disorder | 5 | 1987 | 768 | 0.150 |
Why?
|
| Informed Consent | 2 | 2001 | 1008 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 6403 | 0.140 |
Why?
|
| Needle Sharing | 1 | 2017 | 22 | 0.140 |
Why?
|
| Risk Factors | 21 | 2019 | 74213 | 0.140 |
Why?
|
| Fantasy | 1 | 1997 | 69 | 0.140 |
Why?
|
| Schizophrenia | 16 | 2012 | 6937 | 0.140 |
Why?
|
| Methyltestosterone | 2 | 1994 | 19 | 0.140 |
Why?
|
| Neurosecretory Systems | 1 | 2018 | 223 | 0.140 |
Why?
|
| Antisocial Personality Disorder | 4 | 2015 | 224 | 0.140 |
Why?
|
| United States | 23 | 2019 | 72340 | 0.140 |
Why?
|
| Social Environment | 3 | 2006 | 1020 | 0.130 |
Why?
|
| Suggestion | 1 | 1996 | 21 | 0.130 |
Why?
|
| Mental Processes | 1 | 1998 | 244 | 0.130 |
Why?
|
| Prisoners | 2 | 1997 | 314 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2008 | 1964 | 0.130 |
Why?
|
| Severity of Illness Index | 10 | 2018 | 15843 | 0.130 |
Why?
|
| Opioid-Related Disorders | 5 | 2009 | 2164 | 0.130 |
Why?
|
| Biological Psychiatry | 1 | 1995 | 26 | 0.130 |
Why?
|
| Blood Volume | 2 | 2008 | 547 | 0.130 |
Why?
|
| Disclosure | 1 | 2002 | 748 | 0.130 |
Why?
|
| Commerce | 1 | 2001 | 607 | 0.130 |
Why?
|
| Lithium Carbonate | 9 | 2000 | 179 | 0.130 |
Why?
|
| Cannabis | 2 | 2001 | 441 | 0.130 |
Why?
|
| Time Factors | 14 | 2017 | 39969 | 0.130 |
Why?
|
| Age of Onset | 4 | 2013 | 3306 | 0.130 |
Why?
|
| Hospitals, Psychiatric | 4 | 2012 | 321 | 0.130 |
Why?
|
| Gels | 2 | 2010 | 420 | 0.130 |
Why?
|
| Executive Function | 1 | 2024 | 1392 | 0.130 |
Why?
|
| History, 20th Century | 3 | 2017 | 2767 | 0.130 |
Why?
|
| Nicotinic Agonists | 1 | 1997 | 265 | 0.130 |
Why?
|
| Seroepidemiologic Studies | 1 | 2017 | 397 | 0.130 |
Why?
|
| Certification | 1 | 1999 | 418 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2008 | 17904 | 0.120 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1996 | 353 | 0.120 |
Why?
|
| Depression | 9 | 2011 | 8126 | 0.120 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 15502 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2007 | 3251 | 0.120 |
Why?
|
| Alcohol Drinking | 6 | 2017 | 4028 | 0.120 |
Why?
|
| Citalopram | 1 | 2017 | 402 | 0.120 |
Why?
|
| Sex Offenses | 2 | 1998 | 352 | 0.120 |
Why?
|
| Eye Movements | 1 | 1998 | 511 | 0.120 |
Why?
|
| Linear Models | 4 | 2014 | 5872 | 0.120 |
Why?
|
| Inositol | 1 | 2015 | 215 | 0.120 |
Why?
|
| Personality Development | 1 | 1995 | 244 | 0.120 |
Why?
|
| Personality Inventory | 4 | 2005 | 1019 | 0.120 |
Why?
|
| Brain Damage, Chronic | 1 | 1995 | 267 | 0.110 |
Why?
|
| Sports Medicine | 3 | 2012 | 240 | 0.110 |
Why?
|
| Acetylcarnitine | 1 | 2013 | 9 | 0.110 |
Why?
|
| Drug Therapy, Combination | 12 | 2013 | 6312 | 0.110 |
Why?
|
| Rupture | 1 | 2015 | 443 | 0.110 |
Why?
|
| Thioctic Acid | 1 | 2013 | 28 | 0.110 |
Why?
|
| Feeding Behavior | 6 | 2005 | 3188 | 0.110 |
Why?
|
| Adipose Tissue | 4 | 2004 | 3313 | 0.110 |
Why?
|
| Age Factors | 10 | 2019 | 18399 | 0.110 |
Why?
|
| Adolescent Behavior | 1 | 2002 | 1190 | 0.110 |
Why?
|
| HIV Seropositivity | 1 | 2019 | 960 | 0.110 |
Why?
|
| Epidemics | 1 | 2019 | 512 | 0.110 |
Why?
|
| Hypertrophy | 1 | 2015 | 561 | 0.110 |
Why?
|
| Motor Skills | 2 | 2008 | 521 | 0.110 |
Why?
|
| Residential Treatment | 1 | 2014 | 111 | 0.110 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2009 | 455 | 0.110 |
Why?
|
| Cocaine-Related Disorders | 2 | 2009 | 461 | 0.100 |
Why?
|
| Monoamine Oxidase Inhibitors | 5 | 1989 | 156 | 0.100 |
Why?
|
| Nicotine | 1 | 1997 | 680 | 0.100 |
Why?
|
| Nomifensine | 3 | 1987 | 14 | 0.100 |
Why?
|
| Fitness Centers | 1 | 2012 | 13 | 0.100 |
Why?
|
| Spouse Abuse | 1 | 1994 | 182 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2008 | 3407 | 0.100 |
Why?
|
| Treatment Outcome | 19 | 2014 | 64685 | 0.100 |
Why?
|
| Perimenopause | 1 | 2013 | 142 | 0.100 |
Why?
|
| Child of Impaired Parents | 2 | 1995 | 460 | 0.100 |
Why?
|
| Suicide | 1 | 2023 | 1602 | 0.100 |
Why?
|
| Homicide | 2 | 1996 | 294 | 0.100 |
Why?
|
| Placebos | 9 | 2000 | 1667 | 0.100 |
Why?
|
| Eating | 1 | 2018 | 1539 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 2178 | 0.100 |
Why?
|
| Pilot Projects | 7 | 2016 | 8633 | 0.100 |
Why?
|
| Health Surveys | 3 | 2013 | 4061 | 0.100 |
Why?
|
| Psychosomatic Medicine | 1 | 2012 | 71 | 0.090 |
Why?
|
| Conduct Disorder | 2 | 2011 | 245 | 0.090 |
Why?
|
| Single-Blind Method | 2 | 2010 | 1574 | 0.090 |
Why?
|
| Famous Persons | 1 | 2012 | 109 | 0.090 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2017 | 1141 | 0.090 |
Why?
|
| Clinical Trials as Topic | 15 | 2009 | 8002 | 0.090 |
Why?
|
| Methandrostenolone | 2 | 2006 | 5 | 0.090 |
Why?
|
| Psychotropic Drugs | 8 | 1997 | 888 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2017 | 1567 | 0.090 |
Why?
|
| Universities | 6 | 2001 | 993 | 0.090 |
Why?
|
| Consumer Health Information | 1 | 2013 | 215 | 0.090 |
Why?
|
| Motor Cortex | 3 | 2008 | 1007 | 0.090 |
Why?
|
| Chronic Disease | 5 | 2011 | 9319 | 0.090 |
Why?
|
| Body Weight | 10 | 2013 | 4618 | 0.090 |
Why?
|
| Erectile Dysfunction | 2 | 2011 | 444 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2001 | 12059 | 0.080 |
Why?
|
| Riluzole | 1 | 2009 | 59 | 0.080 |
Why?
|
| Child Abuse | 2 | 1998 | 1077 | 0.080 |
Why?
|
| Branchioma | 1 | 2009 | 17 | 0.080 |
Why?
|
| Obesity | 5 | 2006 | 12947 | 0.080 |
Why?
|
| Dancing | 1 | 2011 | 104 | 0.080 |
Why?
|
| Cohort Studies | 6 | 2023 | 41495 | 0.080 |
Why?
|
| Interview, Psychological | 2 | 2003 | 809 | 0.080 |
Why?
|
| Verbal Behavior | 1 | 2011 | 335 | 0.080 |
Why?
|
| Antidepressive Agents, Tricyclic | 5 | 1996 | 432 | 0.080 |
Why?
|
| Polysomnography | 2 | 1993 | 1848 | 0.080 |
Why?
|
| Tryptophan | 3 | 1996 | 482 | 0.080 |
Why?
|
| Analysis of Variance | 4 | 2005 | 6228 | 0.080 |
Why?
|
| Thyroiditis | 1 | 2009 | 86 | 0.080 |
Why?
|
| Calcium Channels | 1 | 2002 | 620 | 0.080 |
Why?
|
| Bromocriptine | 2 | 1990 | 93 | 0.080 |
Why?
|
| Carbamazepine | 3 | 1994 | 224 | 0.080 |
Why?
|
| Body Mass Index | 10 | 2013 | 12953 | 0.080 |
Why?
|
| Aged | 25 | 2014 | 169310 | 0.080 |
Why?
|
| Impulsive Behavior | 1 | 2011 | 346 | 0.080 |
Why?
|
| Child | 17 | 2009 | 80158 | 0.080 |
Why?
|
| Reaction Time | 3 | 2012 | 2089 | 0.080 |
Why?
|
| Psychological Tests | 2 | 2006 | 640 | 0.080 |
Why?
|
| Neural Pathways | 2 | 2018 | 3060 | 0.080 |
Why?
|
| Fluphenazine | 2 | 1986 | 35 | 0.070 |
Why?
|
| Propylamines | 1 | 1988 | 161 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2019 | 8321 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2019 | 3113 | 0.070 |
Why?
|
| Clomipramine | 3 | 1997 | 54 | 0.070 |
Why?
|
| Long-Term Care | 2 | 2008 | 633 | 0.070 |
Why?
|
| Self Report | 1 | 2019 | 3725 | 0.070 |
Why?
|
| Cricetinae | 2 | 2009 | 2423 | 0.070 |
Why?
|
| History, 19th Century | 2 | 2006 | 720 | 0.070 |
Why?
|
| Clozapine | 2 | 1991 | 504 | 0.070 |
Why?
|
| Amygdala | 1 | 2015 | 1354 | 0.070 |
Why?
|
| Personality | 2 | 1990 | 554 | 0.070 |
Why?
|
| Motivation | 5 | 2001 | 2006 | 0.070 |
Why?
|
| Manuals as Topic | 7 | 1988 | 99 | 0.070 |
Why?
|
| Dibenzazepines | 1 | 1986 | 26 | 0.070 |
Why?
|
| Diet, Reducing | 3 | 2001 | 485 | 0.070 |
Why?
|
| Electroencephalography | 5 | 1996 | 6237 | 0.070 |
Why?
|
| Health Education | 2 | 2012 | 1052 | 0.070 |
Why?
|
| Synaptic Transmission | 2 | 2009 | 1173 | 0.070 |
Why?
|
| Gift Giving | 1 | 2007 | 76 | 0.070 |
Why?
|
| Menopause | 1 | 2014 | 1646 | 0.070 |
Why?
|
| Ipecac | 1 | 1986 | 26 | 0.070 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2008 | 701 | 0.070 |
Why?
|
| Echocardiography, Doppler | 1 | 2010 | 897 | 0.070 |
Why?
|
| Paternal Behavior | 1 | 2006 | 33 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 2850 | 0.070 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2009 | 324 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 2242 | 0.060 |
Why?
|
| Follow-Up Studies | 14 | 2010 | 39106 | 0.060 |
Why?
|
| Cushing Syndrome | 1 | 1987 | 241 | 0.060 |
Why?
|
| Abscess | 1 | 2009 | 606 | 0.060 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 1532 | 0.060 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 2 | 1996 | 8 | 0.060 |
Why?
|
| Tranylcypromine | 4 | 1989 | 30 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2017 | 4471 | 0.060 |
Why?
|
| Drug Administration Schedule | 6 | 2000 | 4853 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2017 | 23996 | 0.060 |
Why?
|
| Imipramine | 3 | 1984 | 98 | 0.060 |
Why?
|
| Paralyses, Familial Periodic | 1 | 1984 | 13 | 0.060 |
Why?
|
| Research Design | 4 | 2008 | 6180 | 0.060 |
Why?
|
| Body Composition | 4 | 2013 | 2426 | 0.060 |
Why?
|
| Family Relations | 2 | 2005 | 317 | 0.060 |
Why?
|
| Homosexuality | 2 | 2001 | 267 | 0.060 |
Why?
|
| Thiophenes | 1 | 2009 | 569 | 0.060 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 836 | 0.060 |
Why?
|
| Writing | 1 | 2006 | 199 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 2010 | 1515 | 0.060 |
Why?
|
| Brain Mapping | 3 | 2018 | 6635 | 0.060 |
Why?
|
| Probability | 1 | 2010 | 2477 | 0.060 |
Why?
|
| Goals | 1 | 2010 | 711 | 0.060 |
Why?
|
| Exercise | 2 | 2001 | 5890 | 0.060 |
Why?
|
| Periodicals as Topic | 3 | 2001 | 1463 | 0.060 |
Why?
|
| Echocardiography | 1 | 2017 | 4989 | 0.060 |
Why?
|
| Affective Disorders, Psychotic | 2 | 1982 | 186 | 0.060 |
Why?
|
| Injections, Intramuscular | 4 | 2000 | 554 | 0.060 |
Why?
|
| Malingering | 1 | 1985 | 75 | 0.060 |
Why?
|
| Stereotyping | 1 | 2006 | 239 | 0.060 |
Why?
|
| Longitudinal Studies | 4 | 2017 | 14608 | 0.060 |
Why?
|
| Anthropometry | 1 | 2009 | 1349 | 0.060 |
Why?
|
| Sleep Deprivation | 1 | 2011 | 846 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2018 | 36426 | 0.060 |
Why?
|
| Incidence | 5 | 2023 | 21355 | 0.060 |
Why?
|
| Canada | 2 | 2001 | 2122 | 0.060 |
Why?
|
| Time | 1 | 2005 | 546 | 0.060 |
Why?
|
| Memory, Short-Term | 2 | 2004 | 982 | 0.060 |
Why?
|
| Schizophrenic Psychology | 7 | 1991 | 1647 | 0.060 |
Why?
|
| Laryngoscopy | 1 | 2009 | 707 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2008 | 1416 | 0.060 |
Why?
|
| Taiwan | 1 | 2005 | 521 | 0.050 |
Why?
|
| France | 2 | 2000 | 497 | 0.050 |
Why?
|
| Social Adjustment | 4 | 2015 | 632 | 0.050 |
Why?
|
| Propiophenones | 3 | 1988 | 28 | 0.050 |
Why?
|
| Cross-Over Studies | 3 | 2000 | 2079 | 0.050 |
Why?
|
| Imagination | 1 | 2004 | 226 | 0.050 |
Why?
|
| Colonic Diseases, Functional | 3 | 2003 | 39 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2017 | 5496 | 0.050 |
Why?
|
| Craniocerebral Trauma | 1 | 1988 | 490 | 0.050 |
Why?
|
| Social Class | 1 | 2012 | 2004 | 0.050 |
Why?
|
| Sleep Stages | 3 | 1993 | 694 | 0.050 |
Why?
|
| MEDLINE | 1 | 2003 | 119 | 0.050 |
Why?
|
| Problem Solving | 1 | 2005 | 443 | 0.050 |
Why?
|
| Patient Care Team | 2 | 2012 | 2521 | 0.050 |
Why?
|
| Migraine Disorders | 4 | 2008 | 1703 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 1935 | 0.050 |
Why?
|
| Logistic Models | 5 | 2004 | 13255 | 0.050 |
Why?
|
| Selection Bias | 1 | 2004 | 359 | 0.050 |
Why?
|
| Cerebral Cortex | 2 | 2018 | 5779 | 0.050 |
Why?
|
| Sensation | 1 | 2004 | 337 | 0.050 |
Why?
|
| Dyslipidemias | 1 | 2010 | 868 | 0.050 |
Why?
|
| Mid-Atlantic Region | 1 | 2002 | 24 | 0.050 |
Why?
|
| Psychomotor Performance | 2 | 2004 | 1882 | 0.050 |
Why?
|
| Memory Disorders | 3 | 2001 | 1199 | 0.050 |
Why?
|
| Analgesics | 1 | 2009 | 1070 | 0.050 |
Why?
|
| Pedigree | 2 | 2006 | 4542 | 0.050 |
Why?
|
| Saliva | 1 | 2006 | 828 | 0.050 |
Why?
|
| Anxiety Disorders | 12 | 2003 | 2720 | 0.050 |
Why?
|
| Boston | 8 | 2008 | 9327 | 0.050 |
Why?
|
| Dexamethasone | 5 | 1984 | 1948 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 2169 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 3 | 2007 | 7391 | 0.050 |
Why?
|
| Feminism | 1 | 2001 | 7 | 0.050 |
Why?
|
| Blood Platelets | 1 | 2002 | 2479 | 0.050 |
Why?
|
| Conversion Disorder | 1 | 1985 | 202 | 0.050 |
Why?
|
| Ambulatory Care | 6 | 2000 | 2775 | 0.050 |
Why?
|
| Child, Preschool | 7 | 2006 | 42232 | 0.050 |
Why?
|
| Retrospective Studies | 9 | 2023 | 80647 | 0.050 |
Why?
|
| Health | 1 | 2004 | 398 | 0.050 |
Why?
|
| Biomedical Research | 2 | 2007 | 3429 | 0.050 |
Why?
|
| Animals | 8 | 2019 | 168475 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 2199 | 0.050 |
Why?
|
| Demography | 1 | 2005 | 1648 | 0.040 |
Why?
|
| Odds Ratio | 4 | 2008 | 9647 | 0.040 |
Why?
|
| Psychometrics | 6 | 1994 | 3065 | 0.040 |
Why?
|
| Ethics, Professional | 1 | 2001 | 100 | 0.040 |
Why?
|
| Sampling Studies | 2 | 1999 | 615 | 0.040 |
Why?
|
| Serotonin | 2 | 1999 | 1041 | 0.040 |
Why?
|
| Nonprescription Drugs | 1 | 2001 | 118 | 0.040 |
Why?
|
| Emigration and Immigration | 1 | 1983 | 397 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2004 | 743 | 0.040 |
Why?
|
| Syndrome | 2 | 2023 | 3267 | 0.040 |
Why?
|
| Auditory Perception | 1 | 2004 | 583 | 0.040 |
Why?
|
| Fever | 2 | 1986 | 1618 | 0.040 |
Why?
|
| China | 1 | 2006 | 2374 | 0.040 |
Why?
|
| Pregnanediol | 1 | 1999 | 18 | 0.040 |
Why?
|
| Androstane-3,17-diol | 1 | 1999 | 20 | 0.040 |
Why?
|
| Trust | 1 | 2004 | 530 | 0.040 |
Why?
|
| Esthetics | 1 | 2001 | 330 | 0.040 |
Why?
|
| Narcotics | 1 | 2001 | 336 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6484 | 0.040 |
Why?
|
| Calcium | 1 | 2002 | 5722 | 0.040 |
Why?
|
| Liability, Legal | 1 | 2001 | 210 | 0.040 |
Why?
|
| Nalbuphine | 1 | 1999 | 20 | 0.040 |
Why?
|
| Verbal Learning | 1 | 2001 | 463 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2006 | 6345 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2010 | 3206 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 2691 | 0.040 |
Why?
|
| Alcoholism | 4 | 2012 | 1973 | 0.040 |
Why?
|
| Fluvoxamine | 1 | 1998 | 78 | 0.040 |
Why?
|
| Competitive Behavior | 1 | 2019 | 78 | 0.040 |
Why?
|
| Income | 1 | 1987 | 1877 | 0.040 |
Why?
|
| Appetite | 1 | 2000 | 247 | 0.040 |
Why?
|
| Socioeconomic Factors | 3 | 2009 | 7828 | 0.040 |
Why?
|
| New England | 1 | 2001 | 1054 | 0.040 |
Why?
|
| Phosphatidylcholines | 1 | 1980 | 405 | 0.040 |
Why?
|
| Bisexuality | 1 | 2000 | 294 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2008 | 3442 | 0.040 |
Why?
|
| Europe | 1 | 2005 | 3420 | 0.040 |
Why?
|
| Suicide, Attempted | 3 | 2003 | 1402 | 0.040 |
Why?
|
| Massachusetts | 7 | 2001 | 8833 | 0.040 |
Why?
|
| Hospitalization | 7 | 1995 | 10721 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2019 | 8601 | 0.040 |
Why?
|
| Data Collection | 1 | 2006 | 3322 | 0.040 |
Why?
|
| Language | 1 | 2006 | 1543 | 0.040 |
Why?
|
| Rheumatology | 2 | 1996 | 615 | 0.030 |
Why?
|
| Social Alienation | 2 | 1990 | 19 | 0.030 |
Why?
|
| Specialty Boards | 1 | 1999 | 235 | 0.030 |
Why?
|
| Epitestosterone | 1 | 1996 | 3 | 0.030 |
Why?
|
| Incest | 1 | 1996 | 19 | 0.030 |
Why?
|
| Bupropion | 3 | 1988 | 304 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2006 | 2727 | 0.030 |
Why?
|
| Amobarbital | 1 | 1996 | 43 | 0.030 |
Why?
|
| Antimanic Agents | 1 | 2000 | 520 | 0.030 |
Why?
|
| Psychopathology | 1 | 2019 | 432 | 0.030 |
Why?
|
| Thinness | 1 | 1999 | 490 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2000 | 962 | 0.030 |
Why?
|
| Patient Compliance | 3 | 2012 | 2690 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2023 | 2707 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2006 | 1937 | 0.030 |
Why?
|
| Frontal Lobe | 2 | 2006 | 1420 | 0.030 |
Why?
|
| Neuropsychology | 1 | 1996 | 107 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2018 | 590 | 0.030 |
Why?
|
| Premenstrual Syndrome | 1 | 1996 | 109 | 0.030 |
Why?
|
| Oxymetholone | 1 | 1995 | 9 | 0.030 |
Why?
|
| Functional Laterality | 3 | 2008 | 2257 | 0.030 |
Why?
|
| Nandrolone | 1 | 1995 | 17 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 1997 | 713 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 1999 | 20100 | 0.030 |
Why?
|
| Facial Pain | 1 | 1996 | 120 | 0.030 |
Why?
|
| Drug Resistance | 2 | 1996 | 1596 | 0.030 |
Why?
|
| Combat Disorders | 1 | 1997 | 301 | 0.030 |
Why?
|
| Commitment of Mentally Ill | 1 | 1995 | 94 | 0.030 |
Why?
|
| Carbon Isotopes | 1 | 1996 | 458 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 2894 | 0.030 |
Why?
|
| Sleep, REM | 3 | 1993 | 595 | 0.030 |
Why?
|
| Amenorrhea | 1 | 1998 | 483 | 0.030 |
Why?
|
| Capgras Syndrome | 1 | 1993 | 9 | 0.030 |
Why?
|
| Regional Blood Flow | 2 | 2008 | 1496 | 0.030 |
Why?
|
| Panic Disorder | 2 | 1994 | 613 | 0.030 |
Why?
|
| Color Perception | 1 | 1995 | 213 | 0.030 |
Why?
|
| Acute Disease | 3 | 1995 | 7237 | 0.030 |
Why?
|
| Neoplasms | 1 | 2023 | 22173 | 0.030 |
Why?
|
| Behavior, Addictive | 1 | 2019 | 462 | 0.030 |
Why?
|
| Gynecomastia | 1 | 1994 | 87 | 0.030 |
Why?
|
| Australia | 1 | 1997 | 1250 | 0.030 |
Why?
|
| Expert Testimony | 1 | 1996 | 364 | 0.030 |
Why?
|
| Delirium | 1 | 1985 | 1668 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 1283 | 0.030 |
Why?
|
| Emotions | 2 | 2004 | 2739 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 1996 | 642 | 0.030 |
Why?
|
| Disease Progression | 1 | 2010 | 13510 | 0.030 |
Why?
|
| Hypertension | 2 | 2010 | 8540 | 0.030 |
Why?
|
| Phosphocreatine | 1 | 2013 | 261 | 0.030 |
Why?
|
| Fura-2 | 1 | 2002 | 107 | 0.030 |
Why?
|
| Cues | 1 | 1998 | 875 | 0.030 |
Why?
|
| Receptors, Dopamine D2 | 1 | 1995 | 485 | 0.030 |
Why?
|
| Hydrocortisone | 5 | 1984 | 1819 | 0.030 |
Why?
|
| Patient Dropouts | 2 | 2012 | 412 | 0.030 |
Why?
|
| TRPC Cation Channels | 1 | 2002 | 111 | 0.020 |
Why?
|
| Sweden | 1 | 2015 | 1379 | 0.020 |
Why?
|
| Phenelzine | 3 | 1989 | 28 | 0.020 |
Why?
|
| Bullying | 1 | 2015 | 232 | 0.020 |
Why?
|
| Hippocampus | 1 | 2005 | 3766 | 0.020 |
Why?
|
| Energy Intake | 1 | 1999 | 2134 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2003 | 10212 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 1999 | 2192 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 1996 | 676 | 0.020 |
Why?
|
| Drug Synergism | 2 | 1988 | 1757 | 0.020 |
Why?
|
| Dissent and Disputes | 1 | 2012 | 146 | 0.020 |
Why?
|
| Semantics | 1 | 1995 | 613 | 0.020 |
Why?
|
| Blood Pressure | 3 | 2000 | 8481 | 0.020 |
Why?
|
| Anxiety | 4 | 2000 | 4573 | 0.020 |
Why?
|
| Aged, 80 and over | 5 | 2008 | 58984 | 0.020 |
Why?
|
| Models, Psychological | 1 | 1995 | 829 | 0.020 |
Why?
|
| Software | 1 | 2004 | 4434 | 0.020 |
Why?
|
| Cerebral Ventriculography | 1 | 1990 | 44 | 0.020 |
Why?
|
| Models, Biological | 1 | 2006 | 9469 | 0.020 |
Why?
|
| Swine Diseases | 1 | 1990 | 61 | 0.020 |
Why?
|
| Sick Role | 1 | 1991 | 229 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 484 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1985 | 3415 | 0.020 |
Why?
|
| Halothane | 1 | 1990 | 200 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1994 | 553 | 0.020 |
Why?
|
| Personality Tests | 1 | 1990 | 81 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2008 | 2927 | 0.020 |
Why?
|
| Narcolepsy | 1 | 1992 | 199 | 0.020 |
Why?
|
| Radioligand Assay | 2 | 1980 | 366 | 0.020 |
Why?
|
| Brazil | 1 | 1994 | 1230 | 0.020 |
Why?
|
| Lorazepam | 1 | 1991 | 154 | 0.020 |
Why?
|
| Hospitals, State | 1 | 1989 | 28 | 0.020 |
Why?
|
| Ego | 1 | 1990 | 98 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2001 | 1730 | 0.020 |
Why?
|
| Pulse | 1 | 1989 | 217 | 0.020 |
Why?
|
| Premenopause | 1 | 2013 | 1039 | 0.020 |
Why?
|
| Atrophy | 1 | 1994 | 1633 | 0.020 |
Why?
|
| Phosphates | 1 | 2002 | 770 | 0.020 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1989 | 165 | 0.020 |
Why?
|
| Cats | 1 | 1990 | 975 | 0.020 |
Why?
|
| Israel | 1 | 2011 | 726 | 0.020 |
Why?
|
| Forensic Psychiatry | 1 | 1990 | 195 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2005 | 3708 | 0.020 |
Why?
|
| Osteoporosis | 1 | 1998 | 1606 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 1989 | 202 | 0.020 |
Why?
|
| Biological Transport | 1 | 2002 | 2091 | 0.020 |
Why?
|
| Twin Studies as Topic | 1 | 2008 | 103 | 0.020 |
Why?
|
| Smoking | 1 | 2004 | 9053 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 1994 | 1814 | 0.020 |
Why?
|
| Prospective Studies | 6 | 1998 | 54423 | 0.020 |
Why?
|
| Symbolism | 1 | 2007 | 34 | 0.020 |
Why?
|
| Education, Continuing | 1 | 2008 | 114 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 3415 | 0.020 |
Why?
|
| Ethics Committees | 1 | 2007 | 51 | 0.020 |
Why?
|
| Psychomotor Agitation | 1 | 1989 | 305 | 0.020 |
Why?
|
| Cohort Effect | 1 | 2006 | 39 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2012 | 909 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2002 | 3597 | 0.020 |
Why?
|
| Health Policy | 1 | 2019 | 2684 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 1990 | 417 | 0.020 |
Why?
|
| Fenfluramine | 1 | 1986 | 58 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 931 | 0.020 |
Why?
|
| Analgesics, Opioid | 2 | 2001 | 3808 | 0.020 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 2400 | 0.020 |
Why?
|
| Population | 1 | 2006 | 141 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2010 | 12149 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 2643 | 0.020 |
Why?
|
| Heart Failure | 1 | 2010 | 11671 | 0.020 |
Why?
|
| Phenytoin | 1 | 1986 | 190 | 0.020 |
Why?
|
| Pemoline | 1 | 1985 | 18 | 0.020 |
Why?
|
| Pain Measurement | 2 | 2009 | 3551 | 0.020 |
Why?
|
| Agoraphobia | 3 | 1993 | 177 | 0.020 |
Why?
|
| Recurrence | 2 | 1991 | 8466 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2011 | 751 | 0.020 |
Why?
|
| Psychoanalytic Therapy | 1 | 2007 | 228 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 1505 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1999 | 4016 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 2791 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 2395 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 6374 | 0.010 |
Why?
|
| Congenital Abnormalities | 1 | 2009 | 709 | 0.010 |
Why?
|
| Myoclonus | 1 | 1985 | 107 | 0.010 |
Why?
|
| Neck | 1 | 2009 | 734 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2001 | 15266 | 0.010 |
Why?
|
| Reality Testing | 1 | 1984 | 24 | 0.010 |
Why?
|
| Family Therapy | 1 | 1986 | 215 | 0.010 |
Why?
|
| Cocaine | 2 | 1990 | 958 | 0.010 |
Why?
|
| Depersonalization | 1 | 1984 | 39 | 0.010 |
Why?
|
| Muscle Rigidity | 1 | 1983 | 41 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2002 | 17635 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 2009 | 908 | 0.010 |
Why?
|
| Histrionic Personality Disorder | 1 | 1983 | 10 | 0.010 |
Why?
|
| Prognosis | 3 | 1996 | 29629 | 0.010 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 1992 | 1081 | 0.010 |
Why?
|
| Professional-Family Relations | 1 | 2007 | 495 | 0.010 |
Why?
|
| Antiparkinson Agents | 1 | 1983 | 184 | 0.010 |
Why?
|
| Educational Status | 1 | 1990 | 2522 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 1986 | 8527 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1990 | 1265 | 0.010 |
Why?
|
| Cataplexy | 1 | 2003 | 61 | 0.010 |
Why?
|
| Gambling | 1 | 1986 | 258 | 0.010 |
Why?
|
| Patient Readmission | 1 | 1996 | 3271 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2013 | 2882 | 0.010 |
Why?
|
| Hyperkalemia | 1 | 1984 | 233 | 0.010 |
Why?
|
| Football | 1 | 1988 | 503 | 0.010 |
Why?
|
| Dopamine | 1 | 1989 | 1607 | 0.010 |
Why?
|
| Psychotherapy, Group | 1 | 1986 | 413 | 0.010 |
Why?
|
| Conflict of Interest | 1 | 2007 | 554 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2009 | 1836 | 0.010 |
Why?
|
| Risk | 3 | 1983 | 9610 | 0.010 |
Why?
|
| Body Height | 2 | 2000 | 1570 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 2007 | 783 | 0.010 |
Why?
|
| Gadolinium | 1 | 2006 | 960 | 0.010 |
Why?
|
| Androstenedione | 1 | 2001 | 131 | 0.010 |
Why?
|
| Beauty | 1 | 2001 | 41 | 0.010 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1983 | 269 | 0.010 |
Why?
|
| Vomiting | 1 | 1984 | 651 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 13446 | 0.010 |
Why?
|
| Forecasting | 1 | 1989 | 2928 | 0.010 |
Why?
|
| Length of Stay | 1 | 1994 | 6426 | 0.010 |
Why?
|
| Dosage Forms | 1 | 1980 | 56 | 0.010 |
Why?
|
| Mitochondria | 1 | 2013 | 3624 | 0.010 |
Why?
|
| Behavior Therapy | 1 | 1986 | 879 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2002 | 5112 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2001 | 367 | 0.010 |
Why?
|
| Social Values | 1 | 2001 | 225 | 0.010 |
Why?
|
| Hyperkinesis | 1 | 1979 | 89 | 0.010 |
Why?
|
| Pituitary-Adrenal System | 1 | 1983 | 552 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2008 | 9001 | 0.010 |
Why?
|
| Barbiturates | 1 | 1979 | 113 | 0.010 |
Why?
|
| Isotopes | 1 | 1999 | 125 | 0.010 |
Why?
|
| Cerebellum | 1 | 2006 | 1501 | 0.010 |
Why?
|
| Amphetamines | 1 | 1979 | 143 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1984 | 2341 | 0.010 |
Why?
|
| Sexuality | 1 | 2001 | 180 | 0.010 |
Why?
|
| Naloxone | 1 | 2001 | 370 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2006 | 1695 | 0.010 |
Why?
|
| Health Personnel | 1 | 2012 | 3335 | 0.010 |
Why?
|
| Chlorpromazine | 1 | 1978 | 111 | 0.010 |
Why?
|
| Pharmacology | 1 | 1978 | 100 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1990 | 3575 | 0.010 |
Why?
|
| Panic | 2 | 1989 | 103 | 0.010 |
Why?
|
| New York City | 1 | 2000 | 731 | 0.010 |
Why?
|
| Morphine | 1 | 2001 | 657 | 0.010 |
Why?
|
| Causality | 1 | 2003 | 1242 | 0.010 |
Why?
|
| Anti-Anxiety Agents | 1 | 1979 | 397 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 18966 | 0.010 |
Why?
|
| Urban Population | 1 | 1985 | 2036 | 0.010 |
Why?
|
| Affective Symptoms | 1 | 1979 | 417 | 0.010 |
Why?
|
| Narcotic Antagonists | 1 | 2001 | 585 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2012 | 4481 | 0.010 |
Why?
|
| Volition | 1 | 1996 | 62 | 0.010 |
Why?
|
| Evoked Potentials | 2 | 1996 | 1047 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 20568 | 0.010 |
Why?
|
| Skinfold Thickness | 1 | 1995 | 162 | 0.010 |
Why?
|
| Reference Standards | 1 | 1999 | 1003 | 0.010 |
Why?
|
| Forensic Medicine | 1 | 1995 | 64 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2001 | 2329 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2001 | 1440 | 0.010 |
Why?
|
| Animals, Domestic | 1 | 1974 | 56 | 0.010 |
Why?
|
| Sequence Analysis | 1 | 1995 | 240 | 0.010 |
Why?
|
| Rural Population | 1 | 1985 | 2287 | 0.010 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 1974 | 139 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2000 | 1475 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 1979 | 1132 | 0.010 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 1974 | 177 | 0.010 |
Why?
|
| Zoonoses | 1 | 1974 | 179 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1996 | 665 | 0.010 |
Why?
|
| Parent-Child Relations | 1 | 1996 | 761 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 4920 | 0.010 |
Why?
|
| Family Characteristics | 1 | 1997 | 1004 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1990 | 18255 | 0.010 |
Why?
|
| Encephalitis | 1 | 1974 | 440 | 0.010 |
Why?
|
| Achievement | 1 | 1972 | 288 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1991 | 641 | 0.010 |
Why?
|
| Pargyline | 1 | 1989 | 19 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1985 | 3763 | 0.010 |
Why?
|
| Phobic Disorders | 1 | 1992 | 439 | 0.010 |
Why?
|
| Receptors, Dopamine | 1 | 1990 | 296 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 14033 | 0.010 |
Why?
|
| Eosinophilia | 1 | 1993 | 560 | 0.000 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 1988 | 54 | 0.000 |
Why?
|
| Dilatation, Pathologic | 1 | 1990 | 527 | 0.000 |
Why?
|
| Costs and Cost Analysis | 1 | 1994 | 1668 | 0.000 |
Why?
|
| Survival Analysis | 1 | 2000 | 10090 | 0.000 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1992 | 710 | 0.000 |
Why?
|
| Schizotypal Personality Disorder | 1 | 1988 | 290 | 0.000 |
Why?
|
| Safety | 1 | 1991 | 1149 | 0.000 |
Why?
|
| Wakefulness | 1 | 1992 | 1265 | 0.000 |
Why?
|
| Health Status | 1 | 1999 | 4077 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1989 | 1541 | 0.000 |
Why?
|
| Aging | 1 | 2004 | 8710 | 0.000 |
Why?
|
| Disease Susceptibility | 1 | 1992 | 1787 | 0.000 |
Why?
|
| Interpersonal Relations | 1 | 1972 | 1436 | 0.000 |
Why?
|
| Base Sequence | 1 | 1995 | 12441 | 0.000 |
Why?
|
| MMPI | 1 | 1984 | 81 | 0.000 |
Why?
|
| Alleles | 1 | 1995 | 6864 | 0.000 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1984 | 139 | 0.000 |
Why?
|
| Influenza, Human | 1 | 1974 | 1521 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1989 | 2048 | 0.000 |
Why?
|
| Remission Induction | 1 | 1989 | 2397 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1992 | 2576 | 0.000 |
Why?
|
| Thioridazine | 1 | 1980 | 33 | 0.000 |
Why?
|
| Swine | 1 | 1990 | 5915 | 0.000 |
Why?
|
| Thyrotropin | 1 | 1984 | 834 | 0.000 |
Why?
|
| Nefopam | 1 | 1978 | 1 | 0.000 |
Why?
|
| Euphoria | 1 | 1978 | 65 | 0.000 |
Why?
|
| Dextroamphetamine | 1 | 1978 | 134 | 0.000 |
Why?
|
| Pregnancy | 1 | 1996 | 29890 | 0.000 |
Why?
|
| Caffeine | 1 | 1978 | 700 | 0.000 |
Why?
|
| Fatigue | 1 | 1978 | 1552 | 0.000 |
Why?
|
| Mutation | 1 | 1995 | 30053 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1974 | 2467 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1974 | 3156 | 0.000 |
Why?
|